PV Bulletin

Class 4 Medicines Defect Notification: Teva UK Ltd, Ponlimsi (Denosumab) 60mg Solution for Injection in Pre-filled Syringe

MHRA issued a Class 4 defect notification for Ponlimsi (Denosumab) 60mg solution for injection, requiring healthcare professionals to check stock for affected batches.

Primary source: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-notification-teva-uk-ltd-ponlimsi-denosumab-60mg-solution-for-injection-in-pre-filled-syringe-el-26-a-slash-27

PV Impact Brief

MonitoringConfidence: high

What changed

MHRA issued a Class 4 medicines defect notification for Ponlimsi (Denosumab) 60mg solution for injection (Teva UK Ltd).

Why it matters

Class 4 defect notifications indicate a potential quality issue that does not pose a serious risk to patient safety but requires action to ensure product integrity and correct usage.

Action needed

Check stock for the affected batches of Ponlimsi (Denosumab) 60mg solution for injection and follow the instructions in the MHRA notice.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Owner

Regulatory Intelligence Lead

Review cadence

Immediate review and action; monitor for updates from MHRA.

Regulatory action details

Action type
Medicines recall/notification
Publication date
2026-06-04
Safety issue
Labelling error on the carton (states 'For application to the skin' instead of 'subcutaneous use'). The product itself is correct and intended for subcutaneous injection.

Affected products

  • Ponlimsi (Denosumab) 60mg Solution for Injection
    Teva UK Ltd
    184472186711188656

PV internal implications

HCPs should note the labeling error. Ensure correct administration (subcutaneous). Report any adverse reactions via Yellow Card.

View regulator source

Evidence and confidence

Confidence: highSource updated: Jun 4, 2026

Full briefing

Practical implication

Check stock for the affected batches of Ponlimsi (Denosumab) 60mg solution for injection and follow the instructions in the MHRA notice.

The MHRA published a Class 4 medicines defect notification for Teva UK Ltd's Ponlimsi (Denosumab) 60mg solution for injection in pre-filled syringes. Healthcare professionals should check their stock for affected batches and follow instructions in the notice.

What changed: MHRA issued a Class 4 medicines defect notification for Ponlimsi (Denosumab) 60mg solution for injection (Teva UK Ltd).

Why it matters: Class 4 defect notifications indicate a potential quality issue that does not pose a serious risk to patient safety but requires action to ensure product integrity and correct usage.

Practical implication: Check stock for the affected batches of Ponlimsi (Denosumab) 60mg solution for injection and follow the instructions in the MHRA notice.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

#Safety Signals#Class 4 Medicines Defect Notification#MHRA#other#firecrawl-agent#regulatory-extraction

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward